IASO 208 / IASO BIO - LARVOL DELTA

IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting ➔ Recruiting

Enrollment open • B Cell Lymphoma • Hematological Malignancies • Oncology

IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

New P1 trial • Hematological Malignancies • Oncology

In Vivo CAR-t generation using an engineered lentiviral vector platform targeting BCMA, CD19 and CD20. (ASH 2025) - "This non-replicating, self-inactivating lentiviral vector was used to deliver transgeneencoding CARs against BCMA with humanized VHH nanobody (IASO 206), CD19 with humanized scFv(IASO 207) and CD20 with humanized VHH nanobody (IASO 208) to T cells through CD7 mediated T celltransduction under a high yield T cell specific promotor/enhancer to ensure T cell specific expression ofCAR structures. In vivo delivery of IASO 207 and 208 to HSC engraftedhumanized mice via single tail vein injection resulted in depletion of both circulating and spleen B cells.Similarly, in vivo delivering of IASO 206 to human PBMC reconstituted NPG mice via single tail veininjection resulted in tumor regression of RPMI-8226 multiple myeloma xenograft without showing anymice toxicity. Taking together, these results validate our platform's ability to generate functional CAR-T cells in vivo,offering a promising off-the-shelf solution for relapsed/refractory multiple myeloma, NHL, and..."

IO biomarker • Preclinical • Viral vector • Graft versus Host Disease • Hematological Malignancies • Immunology • Multiple Myeloma • CD20 • CD7